Pharmacotherapeutic advances for splenomegaly in myelofibrosis

References

• Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703–1719.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International working group for myeloproliferative neoplasms research and treatment). Blood. 2010 Mar 4;115(9):1703–1708.
   PubMed Web of Science ®Google Scholar
• Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996 Aug 1;88(3):1013–1018.
   Google Scholar
• Nores M, Phillips EH, Morgenstern L, et al. The clinical spectrum of splenic infarction. Am Surg. 1998 Feb;64(2):182–188.
   PubMedGoogle Scholar
• Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey. Cancer. 2017 Feb 1;123(3):449–458.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117–1127.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013 Aug 22;122(8):1395–1398.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep;100(9):1139–1145.
   PubMed Web of Science ®Google Scholar
• Mesa R, Harrison C, Oh ST, et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022 Sep;36(9):2261–2268.
   PubMed Web of Science ®Google Scholar
• Polverelli N, Mauff K, Kroger N, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol. 2021 Jan;96(1):69–79.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Soraru M, Dominietto A, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 2010 Mar;45(3):458–463.
   PubMed Web of Science ®Google Scholar
• Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol. 2006;34(5):455–465.
   PubMed Web of Science ®Google Scholar
• Schmidt EE, MacDonald IC, Groom AC. Comparative aspects of splenic microcirculatory pathways in mammals: the region bordering the white pulp. Scanning Microsc. 1993 Jun;7(2):613–628.
   PubMedGoogle Scholar
• Migliaccio AR, Martelli F, Verrucci M, et al. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol. 2008 Feb;36(2):158–171.
   PubMed Web of Science ®Google Scholar
• Wang X, Cho SY, Hu CS, et al. C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol. 2015 Feb;43(2):100–9 e1.
   PubMed Web of Science ®Google Scholar
• Rosti V, Massa M, Vannucchi AM, et al. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007 May-Jun;38(3):280–286.
   PubMed Web of Science ®Google Scholar
• Bogani C, Ponziani V, Guglielmelli P, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008 Aug;26(8):1920–1930.
   PubMed Web of Science ®Google Scholar
• Inra CN, Zhou BO, Acar M, et al. A perisinusoidal niche for extramedullary haematopoiesis in the spleen. Nature. 2015 Nov 26;527(7579):466–471.
   PubMed Web of Science ®Google Scholar
• Migliaccio AR, Martelli F, Verrucci M, et al. Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation. Blood. 2009 Sep 3;114(10):2107–2120.
   PubMed Web of Science ®Google Scholar
• Abdelouahab H, Zhang Y, Wittner M, et al. CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget. 2017 Aug 15;8(33):54082–54095.
   PubMedGoogle Scholar
• Fleischman AG, Aichberger KJ, Luty SB, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011 Dec 8;118(24):6392–6398.
   PubMed Web of Science ®Google Scholar
• Tremblay D, Winters A, Beckman JD, et al. Splanchnic vein thrombosis associated with myeloproliferative neoplasms. Thromb Res. 2022 Oct;218:8–16.
   PubMedGoogle Scholar
• Barosi G, Rosti V, Massa M, et al. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2004 Mar;124(5):618–625.
   PubMedGoogle Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 01;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis [clinical trial, phase III comparative study multicenter study randomized controlled trial research support, non-U.S. Gov’t] The New England J Med. 2012 Mar 1;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016 Aug;30(8):1701–1707.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 Feb 22;10(1):55.
   PubMedGoogle Scholar
• Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc. Natl. Acad. Sci. USA. 2014 Aug 5;111(31):11365–11370.
   Google Scholar
• Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015 Aug;1(5):643–651.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Mesa RA, Jamieson C, et al. Case series of potential Wernicke’s encephalopathy in patients treated with fedratinib. Blood. 2017;130(Supplement 1): 4197-4197.
   Google Scholar
• Pardanani A, Tefferi A, Masszi T, et al. Updated results of the placebo-controlled, phase III Jakarta trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol. 2021 Oct;195(2):244–248.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017 May;4(5):e225–e236.
   PubMed Web of Science ®Google Scholar
• Venugopal S, Mascarenhas J. The odyssey of pacritinib in myelofibrosis. Blood Adv. 2022 Aug 23;6(16):4905–4913.
   PubMedGoogle Scholar
• Mascarenhas J, Virtgaym E, Stal M, et al. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Annals of hematology. 2018 Apr 3.
   Google Scholar
• Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017 Dec 1;35(34):3844–3850.
   PubMed Web of Science ®Google Scholar
• Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017 Mar 30;129(13):1823–1830.
   PubMed Web of Science ®Google Scholar
• Kleppe M, Koche R, Zou L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018 Jan 8;33(1):29–43 e7.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Kremyanskaya M, Patriarca A, et al. S198: Bet Inhibitor Pelabresib (Cpi-0610) Combined With Ruxolitinib In Patients With Myelofibrosis—Jak Inhibitor-Naïve Or With Suboptimal Response To Ruxolitinib—Preliminary Data From The Manifest Study. HemaSphere. 2022;6:99–100.
   Google Scholar
• Mascarenhas J, Kremyanskaya M, Patriarca A, et al. Pelabresib (CPI-0610) combined with ruxolitinib for JAK inhibitor Treatment-naïve patients with myelofibrosis: durability of response and safety beyond week 24. Blood. 2022;140(Supplement 1):586–589.
   Google Scholar
• Guo J, Roberts L, Chen Z, et al. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. PloS one. 2015;10(3):e0114363.
   PubMed Web of Science ®Google Scholar
• Waibel M, Solomon VS, Knight DA, et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013 Nov 27;5(4):1047–1059.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Foran JM, Tandra A, et al. Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: preliminary safety and efficacy in a multicenter, open-label phase 2 study. Am Soc Clin Oncol. 2022.
   PubMedGoogle Scholar
• Ali H, Kishtagari A, Maher K, et al. A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis. Blood. 2022;140(Supplement 1):3986–3987.
   Google Scholar
• Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 Aug 31;130(9):1125–1131.
   PubMed Web of Science ®Google Scholar
• Kuykendall AT, Shah S, Talati C, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar;97(3):435–441.
   PubMed Web of Science ®Google Scholar
• McNamara C, Spiegel J, Xu W, et al. PS1460 LONG-TERM FOLLOW UP OF JAK INHIBITOR (JAKI) TREATED PATIENTS WITH MYELOFIBROSIS: IMPACT OF MOLECULAR ENHANCED INTEGRATED SCORING SYSTEMS AND TYPE OF JAKI THERAPY FAILURE ON SURVIVAL. HemaSphere. 2019;3(S1):672–673.
   Google Scholar
• Palandri F, Breccia M, Bonifacio M, et al. Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020 Mar 15;126(6):1243–1252.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Mehra M, He J, et al. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. J Med Econ. 2020 Jul;23(7):721–727.
   PubMed Web of Science ®Google Scholar
• Schain F, Vago E, Song C, et al. Survival outcomes in myelofibrosis patients treated with ruxolitinib: a population-based cohort study in Sweden and Norway. Eur J Haematol. 2019 Dec;103(6):614–619.
   PubMed Web of Science ®Google Scholar
• Bose P, Verstovsek S. SOHO State of the Art Updates and Next Questions: identifying and Treating “Progression” in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):641–649.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. 2020 Jun;95(6):594–603.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (Jakarta-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017 Jul;4(7):e317–e324.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018 Mar 8.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018 Feb;5(2):e73–e81.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Gerds AT, Vannucchi A, et al. MOMENTUM: phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. Am Soc Clin Oncol. 2022.
   PubMedGoogle Scholar
• Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep;39(9):950–956.
   PubMed Web of Science ®Google Scholar
• Zhou S, Tremblay D, Hoffman R, et al. Clinical benefit derived from decitabine therapy for advanced phases of myeloproliferative neoplasms. Acta Haematol. 2020 Mar;11:1–9.
   Google Scholar
• Masarova L, Verstovsek S, Hidalgo-Lopez JE, et al. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 Oct 18;132(16):1664–1674.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Garcia JS, Somervaille TCP, et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy. J Clin Oncol. 2022 Feb 18;JCO2102188.
   Google Scholar
• Grimwade LF, Happerfield L, Tristram C, et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol. 2009 Nov;147(4):495–506.
   PubMed Web of Science ®Google Scholar
• Yacoub A, Borate U, Rampal R, et al. MPN-127: add-on parsaclisib (a PI3K5 inhibitor) in patients with myelofibrosis and suboptimal response to ruxolitinib: interim analysis from a phase 2 study. Clin Lymphoma Myeloma Leukemia. 2021;21:S354–S355.
   Google Scholar
• Mascarenhas J, Kremyanskaya M, Patriarca A, et al. BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis–JAK-inhibitor naïve or with suboptimal response to ruxolitinib–Preliminary data from the MANIFEST study. In EHA. 2022.
   Google Scholar
• Marchetti M, Barosi G, Cervantes F, et al. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia. 2017 Apr;31(4):882–888.
   PubMed Web of Science ®Google Scholar
• Ferraris AM, Pujic N, Mangerini R, et al. Clonal granulocytes in polycythaemia vera and essential thrombocythaemia have shortened telomeres. Br J Haematol. 2005 Aug;130(3):391–393.
   PubMedGoogle Scholar
• Mascarenhas J, Komrokji RS, Palandri F, et al. Randomized, single-blind, multicenter phase ii study of two doses of imetelstat in relapsed or refractory myelofibrosis. J Clin Oncol. 2021 Sep 10;39(26):2881–2892.
   PubMed Web of Science ®Google Scholar
• Vachani P, Lange A, Delgado RG, et al. Potential disease-modifying activity of navtemadlin (KRT-232), a first-in-class MDM2 inhibitor, correlates with clinical benefits in relapsed/refractory myelofibrosis (MF). Blood. 2021;138(Supplement 1): 3581-3581.
   Google Scholar
• Niebel D, Kirfel J, Janzen V, et al. Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms. Blood. 2014 Jul 3;124(1):151–152.
   PubMed Web of Science ®Google Scholar
• Sprussel A, Schulte JH, Weber S, et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia. 2012 Sep;26(9):2039–2051.
   PubMed Web of Science ®Google Scholar
• Pettit KM, Gill H, Yacoub A, et al. A phase 2 study of the LSD1 inhibitor bomedemstat (IMG-7289) for the treatment of advanced myelofibrosis (MF): updated results and genomic analyses. Blood. 2022;140(Supplement 1):9717–9720.
   Google Scholar
• Tantravahi SK, Kim SJ, Sundar D, et al. A phase 2 study to evaluate the efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors. Blood. 2021;138(Supplement 1): 143-143.
   Google Scholar
• Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006 Jul 15;107(2):361–370.
   PubMed Web of Science ®Google Scholar
• Aruch D, Schwartz M, Mascarenhas J, et al. Continued role of splenectomy in the management of patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):e133–e137.
   PubMedGoogle Scholar
• Lemaire J, Rosiere A, Bertrand C, et al. Surgery for massive splenomegaly. BJS Open. 2017 Feb;1(1):11–17.
   PubMedGoogle Scholar
• Kis B, Mills M, Smith J, et al. Partial splenic artery embolization in 35 cancer patients: results of a single institution retrospective study. J Vasc Interv Radiol. 2019 Aug;27.
   Google Scholar
• Elliott MA, Chen MG, Silverstein MN, et al. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998 Nov;103(2):505–511.
   PubMed Web of Science ®Google Scholar
• Barabanshikova MV, Zubarovsky IN, Savrasov VM, et al. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2019 Sep;12(3):140–145.
   PubMedGoogle Scholar
• Oh ST, Mesa R, Harrison C, et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood. 2022;140(Supplement 1):1518–1521.
   Google Scholar